Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02565511
Other study ID # CAPI015A2201J
Secondary ID 2015-002715-151U
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date November 30, 2015
Est. completion date April 30, 2020

Study information

Verified date July 2021
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.


Description:

The study (also known as the Generation Study 1, GS1) was conducted as part of the Alzheimer's Prevention Initiative (API) program. This trial was a randomized, double-blind, placebo-controlled, parallel group, adaptive design with variable treatment duration planned in cognitively unimpaired APOE4 homozygotes (HMs) aged 60 to 75 years. Participants were enrolled into Cohort I (CAD106) or Cohort II (CNP520). The planned treatment period of 5 to 8 years was not achieved due to early study termination. The study was terminated due to unexpected changes in cognitive function, brain volume loss, and body weight loss. Cohort II (CNP520) treatment was stopped and evaluated through an off-treatment follow-up period. After the decision to terminate Cohort II of the study (CNP520), treatment with CAD106 (Cohort I) was also terminated.


Recruitment information / eligibility

Status Terminated
Enrollment 480
Est. completion date April 30, 2020
Est. primary completion date April 30, 2020
Accepts healthy volunteers No
Gender All
Age group 60 Years to 75 Years
Eligibility Key Inclusion Criteria: - Consented to receive disclosure of their risk estimates to develop clinical symptoms of AD based on their APOE genotype. - Male or female, age 60 to 75 years inclusive. Females were to be post-menopausal. - Mini-Mental State Examination (MMSE) total score = 24 and cognitively unimpaired as evaluated by memory tests - Homozygous APOE4 genotype. - Participant willing to have a study partner. Key Exclusion Criteria: - Any disability that prevented the participant from completing all study requirements. - Current medical or neurological condition that could have impacted cognition or performance on cognitive assessments. - Advanced, severe progressive or unstable disease that may have interfered with the safety, tolerability and study assessments, or put the participant at special risk. - History of malignancy of any organ system, treated or untreated, within 60 months prior to screening. - History of hypersensitivity to any of the investigational drugs or their excipients / adjuvant or to drugs of similar chemical classes. - Indication or on current treatment with ChEIs and/or another AD treatment (e.g. memantine). - Contraindication or intolerance to MRI or PET investigations (with fluorinated radio ligands). - Brain MRI results showing findings unrelated to AD that, in the opinion of the Investigator could have been a leading cause to future cognitive decline, pose a risk to the participant, or prevent a satisfactory MRI assessment for safety monitoring. - Suicidal Ideation in the past six months or Suicidal Behavior in the past two years, prior to screening. - A positive drug screen at Screening, if, in the Investigator's opinion, this was due to drug abuse. - Significantly abnormal laboratory results at Screening, or infection not as a result of a temporary condition. - Current clinically significant ECG findings. For Cohort - I only: Participants with previous organ transplantation or stem cell transplantation, or indication for treatment with anti-coagulants. For Cohort - II only: Participants with depigmenting or hypopigmenting conditions (e.g. albinism vitiligo) or active / history of chronic urticarial in the past year.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CAD106 Immunotherapy
Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
Other:
Placebo to CAD106
Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
Drug:
CNP520
CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
Other:
Placebo to CNP520
Placebo to CNP520 p.o. for the duration of the Treatment Epoch
Alum
Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106

Locations

Country Name City State
Australia Novartis Investigative Site Darlinghurst New South Wales
Australia Novartis Investigative Site Heidelberg Heights Victoria
Australia Novartis Investigative Site Nedlands Western Australia
Belgium Novartis Investigative Site Gent
Belgium Novartis Investigative Site Leuven
Canada Novartis Investigative Site Gatineau Quebec
Canada Novartis Investigative Site Halifax Nova Scotia
Canada Okanagan Clinical Trials Kelowna British Columbia
Canada Novartis Investigative Site Kentville Nova Scota
Canada Novartis Investigative Site London Ontario
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Sherbrooke Quebec
Canada Novartis Investigative Site Sherbrooke Quebec
Canada Novartis Investigative Site Toronto Ontario
Canada The Centre for Memory and Aging Toronto Ontario
Canada Toronto Memory Program Toronto Ontario
Finland Novartis Investigative Site Turku
Germany Novartis Investigative Site Bayreuth
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Boblingen
Germany Novartis Investigative Site Gottingen
Germany Novartis Investigative Site Halle
Germany Novartis Investigative Site Kiel
Germany Novartis Investigative Site Koeln
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Mannheim
Germany Novartis Investigative Site Münster
Germany Novartis Investigative Site Siegen
Germany Novartis Investigative Site Wenzenbach
Netherlands Novartis Investigative Site Amsterdam
Spain Novartis Investigative Site Barcelona
Spain Novartis Investigative Site Barcelona
Spain Novartis Investigative Site Donostia-San Sebastian
Spain Novartis Investigative Site Pozuelo de Alarcon Madrid
Spain Novartis Investigative Site Terrassa Barcelona
Switzerland Novartis Investigative Site Basel CH
United Kingdom Novartis Investigative Site Avon
United Kingdom Novartis Investigative Site Birmingham
United Kingdom Novartis Investigative Site Dundee
United Kingdom Novartis Investigative Site Exeter Devon
United Kingdom Novartis Investigative Site Glasgow
United Kingdom Novartis Investigative Site Glasgow
United Kingdom Novartis Investigative Site Guildford Surrey
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Manchester
United Kingdom Novartis Investigative Site Plymouth Devon
United Kingdom Novartis Investigative Site Westbruy On Trym Bristol
United States Novartis Investigative Site Atlanta Georgia
United States JEM Research Institute Atlantis Florida
United States Senior Adults Specialty Research Austin Texas
United States Novartis Investigative Site Bangor Maine
United States Novartis Investigative Site Basalt Colorado
United States University Hospitals Cleveland Medical Center / Case Western Reserve University Beachwood Ohio
United States The Memory Clinic Bennington Vermont
United States Florida Atlantic University, Clinical Translational Research Unit Boca Raton Florida
United States Novartis Investigative Site Boston Massachusetts
United States Novartis Investigative Site Boston Massachusetts
United States Novartis Investigative Site Centerville Ohio
United States Roper St. Francis - CBRI Charleston South Carolina
United States Alzheimer's Memory Center Charlotte North Carolina
United States Great Lakes Clinical Trials Chicago Illinois
United States Rush University Medical Center Chicago Illinois
United States Medical Research & Health Education Foundation, Inc. Columbus Georgia
United States Novartis Investigative Site Columbus Ohio
United States ATP Clinical Research, Inc. Costa Mesa California
United States Kerwin Research Center & Memory Care Dallas Texas
United States NeuroStudies Decatur Georgia
United States Brain Matters Research Delray Beach Florida
United States Duke University Medical center Durham North Carolina
United States Memory Enhancement Center Eatontown New Jersey
United States University of Kansas Alzheimer's Disease Center Fairway Kansas
United States Triad Clinical Trials, LLC Greensboro North Carolina
United States Clinical Trial Network Houston Texas
United States Houston Methodist Hospital Houston Texas
United States University of Texas Health Science Center, Houston Houston Texas
United States Indiana University Indianapolis Indiana
United States Irvine Center for Clinical Research Irvine California
United States Novartis Investigative Site Jacksonville Florida
United States The Clinical Trial Center, LLC Jenkintown Pennsylvania
United States Novartis Investigative Site Kalamazoo Michigan
United States Novartis Investigative Site Knoxville Tennessee
United States Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas Nevada
United States The Memory Center of Northeastern New York Latham New York
United States Sanders Brown Center on Aging, University of Kentucky Lexington Kentucky
United States University of Southern California Keck School of Medicine Alzheimer Disease Research Center Los Angeles California
United States Meridien Research Maitland Florida
United States CNS Healthcare Memphis Tennessee
United States Advanced Clinical Research Meridian Idaho
United States Merritt Island Medical Research Merritt Island Florida
United States University of Miami Miami Florida
United States Mount Sinai Medical Center - The Wien Center Miami Beach Florida
United States The Medical College of WI Milwaukee Wisconsin
United States Novartis Investigative Site Nashville Tennessee
United States Yale University Alzheimer's Disease Research Unit New Haven Connecticut
United States NYU Langone Medical Center New York New York
United States IPS Research Company Oklahoma City Oklahoma
United States Novartis Investigative Site Oklahoma City Oklahoma
United States Memory Disorders Program, Department of Neurological Sciences, University of Nebraska Medical Center Omaha Nebraska
United States The Nathan S. Kline Institute Orangeburg New York
United States Compass Research Orlando Florida
United States Novartis Investigative Site Orlando Florida
United States Novartis Investigative Site Palo Alto California
United States Novartis Investigative Site Philadelphia Pennsylvania
United States Banner Alzheimer's Institute Phoenix Arizona
United States Novartis Investigative Site Phoenix Arizona
United States Progressive Medical Research Port Orange Florida
United States Memory Health Center at Summit Research Network Portland Oregon
United States Butler Hospital Memory and Aging Program Providence Rhode Island
United States University of Rochester Medical Center Rochester New York
United States Novartis Investigative Site Saint Louis Missouri
United States Novartis Investigative Site Saint Paul Minnesota
United States Novartis Investigative Site San Diego California
United States Syrentis Clinical Research Santa Ana California
United States Novartis Investigative Site Scottsdale Arizona
United States Novartis Investigative Site Sebastopol California
United States California Neuroscience Research Medical Group, Inc. Sherman Oaks California
United States New England Institute for Clinical Research Stamford Connecticut
United States Banner Sun City Research Institute Sun City Arizona
United States Universal Research Group Tacoma Washington
United States USF Health Byrd Alzheimer's Institute Tampa Florida
United States Novartis Investigative Site Temecula California
United States Georgetown University Washington District of Columbia
United States Novartis Investigative Site Washington District of Columbia
United States Via Christi Research Wichita Kansas
United States Abington Neurological Associates Willow Grove Pennsylvania

Sponsors (4)

Lead Sponsor Collaborator
Novartis Pharmaceuticals Amgen, Banner Alzheimer's Institute, National Institute on Aging (NIA)

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  Finland,  Germany,  Netherlands,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia, Due to Alzheimer's Disease (AD)) Event was defined as the first confirmed diagnosis of MCI due to Alzheimer's disease (AD) or dementia due to AD (whichever occurred first) after adjudication by the progression adjudication committee (PAC) as triggered either by an investigator diagnosis or an increase in the Clinical Dementia Rating (CDR) global score. An event had to be confirmed by the PAC at two consecutive visits. In case no confirmed event was observed for a participant, the observation was censored, and the censoring date was defined as the last date where the diagnostic classification was assessed. The Study was terminated and only confirmed events collected up to the data cut-off point were counted. Due to the early termination of the study only a small number of events were observed and time-to-event could not be analyzed. Kaplan-Meyer (KM) estimates were provided to estimate probability that a subject would have an event prior to the specified visit. Baseline to end of exposure for a maximum of 1455 days for CI and 907 days for CII
Primary Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score APCC is a composite score derived from the specific scores from the Repeatable Battery for the Assessment of Neurological Status (RBANS), Mini-Mental State Examination (MMSE) and the Raven's Progressive Matrices. The APCC score is a weighted score with ranges from from 0 to 100 where higher scores correspond to better cognitive performance. CI = Baseline to Weeks 26, 52,78 104 and Baseline to last assessment; CII = Baseline to Weeks 26, 52, 78, 104 and Baseline to Last on-treatment and Baseline to Last off-treatment
Secondary Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Score The CDR was obtained through semi-structured interviews of participants and informants, and cognitive functioning was rated on a 5-point scale of functioning in six domains: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. The CDR global score ranged from zero to three, while the CDR-SOB was the sum of the ratings from the six domains, ranging from 0 to 18 with a minimum increment of 0.5. Higher scores indicated greater disease severity. CI = Baseline to Weeks 26, 52,78 104 and Baseline to last assessment; CII = Baseline to Weeks 26, 52, 78, 104 and Baseline to Last on-treatment and Baseline to Last off-treatment
Secondary Change in the Total Scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Repeatable Battery for the Assessment of Neurological Status (RBANS) is a clinical tool designed to detect and characterize the earliest neurocognitive changes associated with dementia. The RBANS generates age-adjusted index scores for five neurocognitive domains: Immediate Memory, Visuospatial/Constructional, Language, Attention and Delayed Memory, which are used to calculate a Total Scale Index score. Index scores and total score range from 40 to 160 and a higher score indicates better cognitive functioning. CI = Baseline to Weeks 26, 52,78 104 and Baseline to last assessment; CII = Baseline to Weeks 26, 52, 78, 104 and Baseline to Last on-treatment and Baseline to Last off-treatment
Secondary Change in the Index Scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Repeatable Battery for the Assessment of Neurological Status (RBANS) is a clinical tool designed to detect and characterize the earliest neurocognitive changes associated with dementia. The RBANS generates age-adjusted index scores for five neurocognitive domains: Immediate Memory, Visuospatial/Constructional, Language, Attention and Delayed Memory, which are used to calculate a Total Scale Index score. Index scores and total score range from 40 to 160 and a higher score indicates better cognitive functioning. CI = Baseline to Weeks 26, 52 and Baseline to last assessment; CII = Baseline to Weeks 26, 52 and Baseline to Last on-treatment and Baseline to Last off-treatment
Secondary Change in the Everyday Cognition Scale (ECog-Subject) Total Scores Everyday Cognition Scale (ECog) measures cognitively-relevant everyday abilities comprised of 39 items covering 6 cognitively-relevant domains: Everyday Memory, Everyday Language, Everyday Visuospatial Abilities, Everyday Planning, Everyday Organization, and Everyday Divided Attention. The questionnaire is a self-reported measure completed by both participant and study partner (informant). The total score for the 39 items ranges from 39 to 195, with greater scores indicating worse daily function. CI = Baseline to Weeks 26, 52 and Baseline to last assessment; CII = Baseline to Weeks 26, 52 and Baseline to Last on-treatment and Baseline to Last off-treatment
Secondary Change in the Everyday Cognition Scale (ECog-Informant) Total Scores Everyday Cognition Scale (ECog) measures cognitively-relevant everyday abilities comprised of 39 items covering 6 cognitively-relevant domains: Everyday Memory, Everyday Language, Everyday Visuospatial Abilities, Everyday Planning, Everyday Organization, and Everyday Divided Attention. The questionnaire is a self-reported measure completed by both participant and study partner (informant). The total score for the 39 items ranges from 39 to 195, with greater scores indicating worse daily function. Cohort I=C I and Cohort II=C II. CI = Baseline to Weeks 26, 52 and Baseline to last assessment; CII = Baseline to Weeks 26, 52 and Baseline to Last on-treatment and Baseline to Last off-treatment
Secondary Number of Participants With Newly Occurring Safety MRI Abnormalities (ARIA-E, ARIA-H,White Matter Disease and Any Other MRI Abnormalities) Safety MRI included sequences necessary for ascertainment of possible ARIA-E (Amyloid Related Imaging Abnormality-Edema), ARIA-H (Amyloid Related Imaging Abnormality- Hemorrhage, including superficial siderosis and microhemorrhages), assessment of recent infarcts and white matter integrity examination (White matter disease worsening since baseline) and a general assessment of brain abnormalities. Assessment of cerebral amyloid angiopathy (CAA) is included in the overall safety MRI findings results. Baseline to end of exposure for a maximum of 1455 days for CI and 907 days for CII
Secondary Annualized Percent Change on Volume of Brain Regions Annualized % change from baseline in volume of specific brain regions of interest (ROIs): whole brain (WB), hippocampus (Hip), and lateral ventricles (LV). Annualized percentage change was calculated as (percentage per participant / time interval (in days)) x 365.25. Time interval (in days) was derived as date of current MRI assessment on study drug - date of baseline MRI assessment + 1. CI = Baseline to Weeks 26, 52 and Baseline to last assessment; CII = Baseline to Weeks 26, 52 and Baseline to Last on-treatment and Baseline to Last off-treatment
Secondary Change in Cerebrospinal Fluid (CSF) Levels of Amyloid Beta 40 (Aß40) Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): Amyloid Beta 40 (Aß40) Baseline to last assessment
Secondary Change in Cerebrospinal Fluid (CSF) Levels of Amyloid Beta 42 (Aß42) Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): Amyloid Beta 42 (Aß42) Baseline to last assessment
Secondary Change in Cerebrospinal Fluid (CSF) Levels of Total Tau and Phosphorylated Tau Alzheimer's Disease-related biomarkers analyzed in cerebrospinal fluid (CSF): total tau protein and phosphorylated tau protein levels Baseline to last assessment
Secondary Change in Neurofibrillary Tangle Burden as Measured by Standardized Uptake Ratio (SUVR) of PET Scans With Tau Radiotracer (Where Available) To demonstrate the effects of CNP520 vs placebo on tau pathology in the brain Baseline to last assessment
Secondary Cohort I : Annualized Change in Amyloid Deposition as Measured by Centiloids of Positron Emission Tomography (PET) Scan With Amyloid Radiotracer To demonstrate the effects of CAD106 vs placebo on Alzheimer's Disease-related biomarkers Baseline up to approximately Week 104
Secondary Change in Serum Neurofilaments Alzheimer's Disease-related biomarkers analyzed in blood serum: light chain neurofilaments (NfL) Baseline to Week 26 and week 52, CI baseline to last assessment. CII baseline to last on-treatment and to last off-treatment
Secondary Number of Suicidal Ideation or Behavior Events Prospective suicidality assessment was performed with the use of Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire using a detailed branched logic algorithm evaluating participant's suicidality ideation and behavior. Answer "yes" on item 4 or 5 of the Suicidal Ideation section or "yes" on any item of the Suicidal Behavior section was considered positive. Baseline to end of exposure for a maximum of 1455 days for CI and 907 days for CII
Secondary Cohort I : Change in Cognition as Measured by APCC and CDR-SOB Scores and Antibody Response Month 6 to Month 60
Secondary Cohort I: Peak Concentration (Cmax) of CAD106 Induced Abeta-specific Antibody Titers Cmax is the maximum Titer Concentration of any post-baseline 'on treatment' visit. A visit is considered as 'on treatment' if visit date is within {last injection + 180 days}.
- Geometric mean and CI's are back-transformed from the estimates for Log mean and CI's.
Week 9, 13, 15, 26 and quarterly thereafter (trough values)
Secondary Cohort I: Area Under the Concentration Curve (AUC) of CAD106 Induced Abeta-specific Antibody Titers AUC is calculated based on 'on treatment' visit only.(missing values for peak visits were linearly interpolated for calculation; missing values for trough visits were imputed by average of non-missing trough values.). Week 9, 13, 15, 26 and quarterly thereafter (trough values)
See also
  Status Clinical Trial Phase
Completed NCT02409082 - Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures N/A
Completed NCT01993836 - Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care Phase 4
Terminated NCT05097131 - An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
Completed NCT00448799 - Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls Phase 1
Recruiting NCT04639050 - Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Terminated NCT06424236 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation Phase 2/Phase 3
Active, not recruiting NCT05891496 - A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease Phase 3
Terminated NCT01733355 - A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807 Phase 0
Terminated NCT01723488 - A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808 Phase 0
Completed NCT00911690 - Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders N/A
Recruiting NCT01479855 - Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type N/A
Completed NCT01469351 - Identifying Potential Effects of Liraglutide on Degenerative Changes N/A
Completed NCT00439010 - Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects Phase 1
Recruiting NCT05269394 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) Phase 2/Phase 3
Recruiting NCT01760005 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 Phase 2/Phase 3
Completed NCT04623242 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Phase 2/Phase 3
Suspended NCT05552157 - A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation Phase 2/Phase 3
Completed NCT04023994 - A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants Phase 1
Terminated NCT03131453 - A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Phase 2/Phase 3
Completed NCT01946243 - The Feasibility of Florbetapir Quantitation Phase 4

External Links